These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study. Catapano F; Perris F; Masella M; Rossano F; Cigliano M; Magliano L; Maj M J Psychiatr Res; 2006 Sep; 40(6):502-10. PubMed ID: 16904424 [TBL] [Abstract][Full Text] [Related]
26. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497 [TBL] [Abstract][Full Text] [Related]
27. Predictors of benzodiazepine use in a transdiagnostic sample of panic disorder, social anxiety disorder, and obsessive-compulsive disorder patients. Laurito LD; Loureiro CP; Dias RV; Vigne P; de Menezes GB; Freire RC; Stangier U; Fontenelle LF Psychiatry Res; 2018 Apr; 262():237-245. PubMed ID: 29475102 [TBL] [Abstract][Full Text] [Related]
28. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]